Personally I think fda feedback on endpoints, capex requirements, and plan around # of ph3 trials are uncertainties the market is waiting to have cleared. Yes all bio techs have uncertainties but I also think neu is in a different class to others now that it is revenue generating and in the asx200, unknowns and risk weigh more heavily for institutions wanting to invest.
Ann: Update - Notification of buy-back - NEU, page-43
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.000(0.00%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.32 | $7.219M | 577.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2968 | $12.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.57 | 540 | 1 |
View Market Depth
| Last trade - 16.16pm 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |